Celladon Appoints Cleveland as New President, CFOMonday, June 2, 2014
San Diego biotech Celladon Corp. has appointed industry veteran Paul Cleveland as its new president and chief financial officer. Cleveland most recently was CFO of Aragon Pharmaceuticals Inc., a San Diego drugmaker sold to Johnson & Johnson last August for $1 billion.
Celladon began trading publicly Jan. 30 of this year with a $44 million IPO; its most advanced drug, Mydicar, uses gene therapy to target an enzyme that’s deficient in patients with heart failure.
Before Cleveland’s tenure at Aragon, he was a general partner and chief operating officer of Menlo Park firm Mohr Davidow Ventures. From 2006 to 2011 he served in leadership roles – including CFO — of Affymax Inc., a publicly traded Bay Area biotech. He has served as a JPMorgan investment banker, as well as a corporate lawyer at Davis Polk & Wardwell, Sidley & Austin, and Cooley LLP.
“We expect Paul’s vast experience as a senior industry executive will lead to important contributions to Celladon,” CEO Krisztina Zsebo said in a statement. “We look forward to his expertise and leadership as we further advance Mydicar through development and toward commercialization.”